Strides gains USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg EP News Bureau Sep 6, 2024 Strides is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity for Theophylline Extended-Release Tablets, 300…
